ID   KPD
AC   CVCL_B412
SY   KPDXM
DR   BTO; BTO_0006421
DR   cancercelllines; CVCL_B412
DR   Cosmic; 1529900
DR   GEO; GSM879216
DR   IARC_TP53; 27030
DR   Progenetix; CVCL_B412
DR   Wikidata; Q54900430
RX   PubMed=2457439;
RX   PubMed=17354236;
RX   PubMed=19787792;
RX   PubMed=21519327;
RX   PubMed=23144859;
CC   Doubling time: ~36 hours (PubMed=21519327).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792).
CC   Omics: SNP array analysis.
CC   Caution: Indicated as originating from a 7 year old female patient in PubMed=19787792 and from a 8 year old male patient in PubMed=17354236. The STR profile has Amelogenin X,Y.
CC   Derived from site: In situ; Bone, femur; UBERON=UBERON_0000981.
ST   Source(s): PubMed=19787792
ST   Amelogenin: X,Y
ST   D16S539: 11,13
ST   D18S51: 10,13
ST   D19S433: 13.2,14
ST   D21S11: 30,31.2
ST   D2S1338: 20,24
ST   D3S1358: 17
ST   D5S818: 9,11
ST   D8S1179: 13,15
ST   FGA: 21
ST   SE33: 27.2
ST   TH01: 9,9.3
ST   TPOX: 8,9
ST   vWA: 19
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   8Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 17
//
RX   PubMed=2457439;
RA   Bruland O.S., Fodstad O., Stenwig A.E., Pihl A.;
RT   "Expression and characteristics of a novel human osteosarcoma-associated
RT   cell surface antigen.";
RL   Cancer Res. 48:5302-5309(1988).
//
RX   PubMed=17354236; DOI=10.1002/ijc.22643;
RA   Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G.,
RA   Myklebost O.;
RT   "Potential for treatment of liposarcomas with the MDM2 antagonist
RT   Nutlin-3A.";
RL   Int. J. Cancer 121:199-205(2007).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=21519327; DOI=10.1038/labinvest.2011.72;
RA   Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M.,
RA   Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.;
RT   "Functional characterization of osteosarcoma cell lines provides
RT   representative models to study the human disease.";
RL   Lab. Invest. 91:1195-1205(2011).
//
RX   PubMed=23144859; DOI=10.1371/journal.pone.0048262; PMCID=PMC3492335;
RA   Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H.,
RA   Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E.,
RA   Myklebost O., Meza-Zepeda L.A.;
RT   "Integrative analysis reveals relationships of genetic and epigenetic
RT   alterations in osteosarcoma.";
RL   PLoS ONE 7:E48262-E48262(2012).
//